CalciMedica, Inc. Common Stock Total Liabilities
CalciMedica, Inc. Common Stock total liabilities. Based on the latest financial reports, CalciMedica, Inc. Common Stock (CALC) has total liabilities worth $20.23 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CalciMedica, Inc. Common Stock (CALC) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CalciMedica, Inc. Common Stock (2018–2025)
Total liabilities of CalciMedica, Inc. Common Stock from 2018 to 2025. This chart illustrates how CalciMedica, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
CalciMedica, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of CalciMedica, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Medadvisor Ltd
AU:MDR
|
Australia | AU$41.46 Million |
|
Acme Holdings Bhd
KLSE:7131
|
Malaysia | RM94.22 Million |
|
Larq SA
WAR:LRQ
|
Poland | zł12.86 Million |
|
TWZ Corporation Public Company Limited
BK:TWZ
|
Thailand | ฿2.20 Billion |
|
TAG Oil Ltd.
V:TAO
|
Canada | CA$2.43 Million |
|
Meta Epsi Tbk PT
JK:MTPS
|
Indonesia | Rp31.10 Billion |
|
Clean & Science co. Ltd
KQ:045520
|
Korea | ₩54.59 Billion |
|
Techcential International Ltd
TWO:6616
|
Taiwan | NT$317.43 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down CalciMedica, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CALC total asset value.
Liquidity & Leverage Metrics
CalciMedica, Inc. Common Stock Total Liabilities Ratios Explained
CalciMedica, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CalciMedica, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CalciMedica, Inc. Common Stock (2018–2025)
The table below shows the annual total liabilities of CalciMedica, Inc. Common Stock from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $20.23 Million | +275.78% |
| 2024-12-31 | $5.38 Million | +33.66% |
| 2023-12-31 | $4.03 Million | -67.99% |
| 2022-12-31 | $12.58 Million | +209.52% |
| 2021-12-31 | $4.07 Million | -41.99% |
| 2020-12-31 | $7.01 Million | -42.80% |
| 2019-12-31 | $12.25 Million | +111.44% |
| 2018-12-31 | $5.79 Million | -- |
About CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxi… Read more